Bibliografía del artículo
1. Krumholz HM. Cardiopatía isquémica en el anciano. Rev Esp Cardiol 2001; 54: 819-826.
2. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311-22.
3. Tiefenbrun AJ, Chandra NC, French WJ, y Col. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction. (NRMI-2). J Am Coll Cardiol. 1998;31:1240 -1245.
4. El anciano con cardiopatía. Manual para un abordaje integral del enfermo de edad avanzada con enfermedades cardiovasculares. Coordinador: M. Martínez Sellés. 2010. Sociedad española de cardiología. Ed. Acción Médica. ISNB 978-84-88336-94-1.
5. Steg G, James S, Atar D, y col. Task Force on the management of ST-segment elevation acute myocardial infarction, ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. European Heart Journal doi:10.1093/eurheartj/ehs215.
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;ii:349-60.
7. Sinnaeve PR, Huang Y, Bogaerts K, y col. The ASSENT 3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT 3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.
8. Peters RJ, Joyner C, Bassand JP y col. For the OASIS-6 Investigators. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J. 2008;29:324-31.
9. White HD, Yusuf S. Issues regarding the use of heparin following streptokinase therapy. J Thromb Thrombolysis. 1995;2:5-10.
10. Chen ZM, Pan HC, Chen YP, y col. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622-32.
11. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-685.
12. Pitt B, Remme W, Zannad F, y col. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
13. White HD, Barbash GI, Califf RM y col. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. Circulation. 1996;94: 1826-1833.
14. Thiemann DR, Coresh J, Schulman SP, y col. Lack of benefit for intravenous trhombolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000; 101:2239-46
15. Berger AK, Radford MJ, Wang Y, y col. Thrombolytic therapy in older patients. J Am Coll Cardiol. 2000;36:366 -374.
16. Bueno H, Martínez-Sellés M, Pérez-David E, y col. Effect of thrombolytic therapy on the risk of cardiac rupture and mortality in older patients with first acute myocardial infarction Eur Heart J 2005: 26, 1705-1711
17. Boucher JM, Racine J, Thanh TH y col. Quebec Acute Coronary Care Working Group. Age-related differences in in-hospital mortality and the use of thrombolytic therapy for acute myocardial infarction. CMAJ. 2001;164:1285-1290.
18. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
19. de Boer MJ, Ottervanger JP, Van´t Hof AWJ y col. On behalf of the Zwolle Myocardial Infarction Study Group. Reperfusion therapy in elderly patients with acute myocardial infarction. A randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002;39:1723-1728.
20. Grines C. Senior PAMI. Primary angioplasty versus thrombolytic therapy for acute myocardial infarction in the elderly. http://www.clinicaltrial.gov/ct2/show/NCT00136929.(14 May 2010).
21. Bardají A, Bueno H, Fernández-Ortiz A y col. En representación de los investigadores del Registro TRIANA. Tratamiento y evolución a corto plazo de los ancianos con infarto agudo de miocardio ingresados en hospitales con disponibilidad de angioplastia primaria. El Registro TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos). Rev Esp Cardiol 2005;58:351-358.
22. Bueno H, Betriu A, Heras M y col. On behalf of the TRIANA investigators. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur Heart J. 2011;32:51-60.